Application of doxorubicin-induced rAAV2-p53 gene delivery in combined chemotherapy and gene therapy for hepatocellular carcinoma. [electronic resource]
Producer: 20080905Description: 303-9 p. digitalISSN:- 1555-8576
- Antibiotics, Antineoplastic -- therapeutic use
- Carcinoma, Hepatocellular -- genetics
- Cell Line, Tumor
- Cell Survival -- drug effects
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Combined Modality Therapy
- Dependovirus -- genetics
- Dose-Response Relationship, Drug
- Doxorubicin -- therapeutic use
- Fluorescent Dyes -- metabolism
- Gene Transfer Techniques
- Genes, Reporter
- Genes, p53
- Genetic Therapy
- Green Fluorescent Proteins -- metabolism
- Humans
- Liver Neoplasms -- genetics
- Luciferases -- metabolism
- Tumor Suppressor Protein p53 -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.